Andra AP fonden Sells 27,400 Shares of IQVIA Holdings Inc. $IQV

Posted by Francis Steltz on Sep 22nd, 2026

Andra AP fonden lowered its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 22.6% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 94,005 shares of the medical research company’s stock after selling 27,400 shares during the period. Andra AP fonden owned about 0.06% of IQVIA worth $18,164,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Compass Financial Management LLC bought a new stake in shares of IQVIA in the 2nd quarter worth approximately $27,000. Financial Freedom LLC purchased a new position in IQVIA during the 1st quarter valued at $25,000. Ascentis Independent Advisors purchased a new stake in IQVIA in the first quarter worth $25,000. Elevation Wealth Partners LLC increased its stake in shares of IQVIA by 218.8% during the second quarter. Elevation Wealth Partners LLC now owns 153 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 105 shares in the last quarter. Finally, Hilton Head Capital Partners LLC purchased a new position in shares of IQVIA in the 4th quarter worth about $35,000. 89.62% of the stock is owned by institutional investors.

Insider Transactions at IQVIA

In related news, insider Bhavik Patel sold 1,855 shares of the firm’s stock in a transaction that occurred on Friday, July 31st. The stock was sold at an average price of $235.27, for a total value of $436,425.85. Following the sale, the insider owned 1,348 shares of the company’s stock, valued at approximately $317,143.96. This trade represents a 57.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider James G. Berkshire sold 2,668 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total transaction of $697,228.44. Following the transaction, the insider directly owned 10,890 shares in the company, valued at approximately $2,845,883.70. The trade was a 19.68% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 15,581 shares of company stock valued at $3,796,021 in the last quarter. Insiders own 1.70% of the company’s stock.

IQVIA Trading Up 0.5%

IQV stock traded up $1.22 during mid-day trading on Tuesday, hitting $271.10. 200,371 shares of the company were exchanged, compared to its average volume of 1,736,111. IQVIA Holdings Inc. has a 12-month low of $154.50 and a 12-month high of $273.88. The firm has a market capitalization of $44.62 billion, a P/E ratio of 33.66, a PEG ratio of 2.28 and a beta of 1.18. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. The business has a fifty day simple moving average of $243.93 and a 200-day simple moving average of $200.29.

IQVIA (NYSE:IQV – Get Free Report) last announced its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm had revenue of $4.37 billion during the quarter, compared to analysts’ expectations of $4.30 billion. During the same period in the previous year, the company earned $2.81 earnings per share. IQVIA’s quarterly revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities research analysts predict that IQVIA Holdings Inc. will post 11.56 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. HSBC reaffirmed a “buy” rating and set a $240.00 target price on shares of IQVIA in a report on Monday, July 6th. TD Cowen upped their price target on shares of IQVIA from $233.00 to $288.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. Barclays reiterated an “overweight” rating on shares of IQVIA in a report on Tuesday, July 28th. Mizuho boosted their price objective on shares of IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Finally, Deutsche Bank Aktiengesellschaft set a $240.00 price target on shares of IQVIA in a report on Thursday, July 9th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $248.00.

Get Our Latest Stock Analysis on IQVIA

IQVIA Company Profile

(Free Report)

IQVIA Holdings Inc is a global provider of advanced analytics, technology solutions and contract research services for the life sciences industry. The company supports pharmaceutical, biotechnology and medical device companies throughout the product life cycle, from research and clinical development through commercialization and post-market activities.

Its offerings include clinical trial management, site and patient services, real-world evidence, healthcare data, regulatory and safety services, commercial analytics, consulting, and technology platforms.